In touch with science – to success in market!
Our focus
IBR Inc., Institute for Biopharmaceutical Research is a Swiss GxP-compliant contract research organization founded in 1998. We are a first-in-class site in the field of bioanalytical services for new biological entities (NBE), like therapeutic antibodies, as well as new chemical entities (NCE), antibody-drug conjugates and vaccines. We are covering the bioanalytical needs from discovery over pre-clinical to clinical development and market.
We are experienced in driving studies on cytokines, chemokines and other biomarkers, drug/target binding and immunogenicity. Furthermore, we perform cell-based assays with a broad variety of readouts. Our team has vast experience with primary cells, transformed cell lines, transfected cells, reporter-gene cell systems and 3D cell-based assays.
IBR Inc. moves on with rapid and constantly growing advances in technology and offers advanced platforms including Alpha Technology, Time Resolved Fluorescence (TRF), MSD® ECL, Gyrolab™, state-of-the-art Flow Cytometry / Cytometric Bead Array and real time PCR, beside a broad variety of classical techniques.
With IBR Inc. your studies are supported from assay development to assay validation and sample measurement. We have capability to perform studies in compliance with regulatory guidelines for GLP, GMP and GCP quality standards, following the principles of ICH Q2 (R1), USP 1032, 1033, 1034 and the EU GMP requirements. Our study reports are compliant with eCTD requirements.